Application of beta-alanine in preparation of medicine for treating pulmonary arterial hypertension
By inhibiting lactate-mediated histone lactylation modification with β-alanine, the pathological phenotypic transformation of smooth muscle cells is blocked, solving the problem that existing pulmonary hypertension drugs cannot inhibit vascular remodeling and achieving effective treatment of pulmonary hypertension.
CN121102187APending Publication Date: 2025-12-12SHANGHAI FIRST PEOPLES HOSPITAL
0 Cites 1 Cited by
Patent Information
- Application Number
- CN202511481022.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-16
- Publication Date
- 2025-12-12
AI Technical Summary
Technical Problem
Existing drugs for pulmonary hypertension cannot effectively inhibit pulmonary vascular remodeling, have single targets, and have limited long-term therapeutic effects, failing to fundamentally improve disease progression.
Method used
By competitively inhibiting lactate-mediated histone lactylation modification using β-alanine, pathological phenotypic transformation of smooth muscle cells is blocked, thus inhibiting vascular remodeling.
Benefits of technology
By inhibiting histone lactylation modification, β-alanine significantly improves pulmonary artery wall remodeling, reduces pulmonary artery pressure, alleviates right ventricular hypertrophy, reverses the pathological process of pulmonary hypertension, and improves patient survival.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses an application of beta-alanine in preparation of a medicine for treating pulmonary arterial hypertension. In-vivo and in-vitro pharmacological experiments prove that beta-alanine can inhibit lactic acid-mediated histone milk acylation modification and hypoxia-induced phenotypic transformation of PASMCs (Polyaspartic Sulfonate Molecules); the hemodynamics and pulmonary artery vascular remodeling of the PAH mouse are improved. The beta-alanine can inhibit phenotypic transformation of PASMCs and reverse pulmonary artery vascular remodeling which is a key pathological change in the pulmonary hypertension generation process, has huge potential in treatment of pulmonary hypertension, and has good application prospects and high clinical application value.
Need to check novelty before this filing date? Find Prior Art